Neurodome
Neurodome, Inc.
Brain-computer interface, as a core track of future industries, is in a period of rapid development driven by both capital and technology. Recently, Neurodome, Inc. (referred to as "Neurodome"), which focuses on therapeutic brain-computer interfaces, announced the completion of nearly 100 million yuan in its A+ round of financing.
This round was led by Mingxi Capital, with Optics Valley Industrial Investment following on. Existing shareholders including Shunwei Capital, Huafang Capital, iFlytek Ventures, and Oriza Origins continued to increase their investments. Chasing Far & Beyond served as the exclusive financial advisor. Notably, Mingxi Capital, the lead investor of this round, was jointly established by A-share listed company Mindray Biotech and Legend Capital.
This investment in Neurodome marks Mingde Bio's official entry into the brain-computer interface sector through industrial capital, further enhancing its strategic layout in the life and health field. It is reported that this round of financing will mainly be allocated to product iteration, clinical registration advancement, business expansion, and innovative technology exploration.
|Led by the XJTU Team, Integration of Medicine and Engineering Strengthens Technical Foundation
Public information shows that the core team of Neurodome mainly comes from the Institute of Biomedical Engineering at the School of Life Sciences, Xi'an Jiaotong University. They have substantial technical reserves and accumulation in neuromodulation. Since 2015, they have been focusing on TI technology, and were approved for a related National Natural Science Foundation project in 2017. Over the past eight years, they have conducted nearly a thousand animal experiments and nearly a hundred human clinical trials.
Among them, Dr. Long Li, co-founder and CEO of Neurodome, is currently an associate professor in the School of Chemistry at the university. He has an interdisciplinary background in electronic engineering and biomedical engineering. He completed his undergraduate studies in Electronic Information Engineering at Xi’an Jiaotong University (XJTU), and later pursued a Ph.D. in Biomedical Engineering due to his interest, under the guidance of Professor Jue Wang, a leading expert in China’s neuromodulation field. Outside of academic research, Long Li previously worked at ZTE Corporation, where he participated in the development of 5G base stations and 4G RF antennas, gaining extensive experience in industrial transformation.
Dr. Long Li, Co-founder and CEO of Neurodome
His mentor, Professor Wang Jue, is a co-founder and chief scientist of Neurodome. He has led teams in undertaking key projects of the National Natural Science Foundation and the 863 Program, and is a renowned expert in China's neuromodulation field, serving as the vice chairman of the Chinese Neuromodulation Association.
In addition, Professor Liu Tian, the co-founder and CTO, is currently a professor at the School of Life Sciences of Xi'an Jiaotong University, focusing on the research and development of neuromodulation technology. Together with Dr. Li Long, they formed a technical team centered around the brain science team of Xi'an Jiaotong University. The team has been conducting related research since 2012 and initiated commercial applications in 2019.
丨Deepening TI Technology, Building a Non-invasive Deep Brain Modulation Barrier
Neurodome, founded in 2019, focuses on the research and application of non-invasive deep brain neuromodulation technology. Its products are mainly used for the treatment of multiple systemic diseases such as Parkinson's disease, epilepsy, depression, and pain. Currently, there are nearly 130 million patients with brain-related diseases in China, and there is an urgent clinical need for non-invasive and precise long-term intervention methods. The mainstream technologies at present each have limitations: deep brain stimulation (DBS) is effective but requires craniotomy to implant electrodes, leading to low patient acceptance and a penetration rate of only 1.1%; transcranial magnetic stimulation (TMS), while non-invasive, lacks precision and has low compatibility with conditions like Parkinson’s disease.
The core technology of Neurodome is its independently developed Time Interference (TI) stimulation technology, which enables high-precision modulation of deep brain regions under non-invasive conditions, overcoming the drawbacks of traditional Deep Brain Stimulation (DBS) that require craniotomy for electrode implantation.
Non-invasive stimulation is achieved by generating "interference" in deep brain regions through high-frequency current from external electrodes, combining safety with precision. Its advantages include: no craniotomy required, reducing treatment risks; stimulation range covering 0-80mm beneath the skull, applicable to various neurological disorders such as Parkinson's disease, depression, autism, and epilepsy; modular design enhances individual adaptability, and the cost is only one-third of DBS, providing a better solution for clinical use.
At the same time, the company has formed a systematic lead in key dimensions such as non-invasiveness, modulation depth, spatial precision, and multi-target synergy, taking the lead in achieving and mastering the capability of precise non-invasive deep brain neural modulation in the human body using TI.
From the actual data of clinical and commercial implementation, Neurodome, relying on its full-chain TI platform covering "proof-of-principle—technical iteration—clinical transformation," has established cooperation with over 200 research and medical institutions at home and abroad, spanning nearly 50 indications in scientific research and clinical exploration. The market share of related equipment reaches 87%, and it has been adopted by more than 10 overseas neuroscience laboratories, with multiple indication GCP clinical trials currently underway.
On this basis, the company has built the "TI-FUSION Multimodal Synergistic Neuromodulation System" product matrix and further locked its core direction into therapeutic brain-computer interfaces. It is developing high-precision non-invasive stimulation and signal acquisition technologies represented by focused ultrasound (such as the NervioTUS system). Through array design and phased-array modulation, combined with an adaptive closed-loop mechanism of multimodal biomarkers, the company aims to push neuromodulation from one-way stimulation towards a dynamic intervention model of "sensing-regulation-optimization," establishing a cutting-edge technological platform for therapeutic brain-computer interfaces targeting complex nervous system diseases.
Therefore, the leading technology roadmap, solid clinical data, and absolutely dominant market share enable Neurodome to gradually build an industry barrier with both technological and market attributes in the niche track of non-invasive deep brain modulation.
However, Neurodome's goal is not limited to technological breakthroughs but directly aims at import substitution. Its official website explicitly benchmarks its products against Medtronic's DBS series — this U.S. medical technology giant, founded in 1949, covers multiple fields such as arrhythmia and neurological disorders, with its brain pacemaker being the core device in DBS therapy.
丨Top Institutions Gather, Mingxi Capital Doubles Down
Solid underlying capabilities have also attracted continuous heavy investment from the capital market. Since completing its angel round of financing in 2022, Neurodome has maintained a steady and efficient pace of development, successively completing its Pre-A, A, and A+ rounds of financing, with its investor base continuously expanding.
Since its establishment, the company has gathered more than ten top-tier institutions, including Mingxi Capital, Shunwei Capital, Frees Fund, Huafang Capital, iFlytek Ventures, Oriza Genesis, Optics Valley Industrial Investment, Shaanxi Growth Fund, China-Singapore Group, and Xi'an Finance.
The intensive injection of multiple rounds of capital not only verifies Neurodome's hardcore strength in Time Interference (TI) technology and its clinical commercialization potential, but also demonstrates the market's firm confidence in its ability to reshape the therapeutic brain-computer interface industry landscape and set a new paradigm for non-invasive deep brain precision regulation.
| In conclusion
Driven by both policy and market forces, brain-computer interface technology is being pushed to an unprecedented developmental boom. In March 2026, the "Government Work Report" mentioned brain-computer interfaces for the first time, identifying them as a key future industry for fostering new productive capabilities. The Ministry of Industry and Information Technology and six other departments jointly issued a document proposing the goal of nurturing 2-3 global leading companies by 2030.
Behind the policy红利 is a clinical刚需亟待满足 for nearly 130 million brain disease patients in China. Facing this billion-dollar蓝海市场, therapeutic brain-computer interfaces are accelerating from laboratories towards large-scale commercial落地, and China is expected to become the fastest-growing core market globally.
The leading investment by Mingxi Capital, a subsidiary of Mingde Biotech, sends a clear signal — traditional medical listed companies are deeply deploying brain-computer interface through industrial investment to seize the high ground of future medical technology.
Clearly, standing at the forefront of the resonance among policy, capital, and technology, Neurodome is participating as a core player.